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1. INTRODUCTION {#gcc22737-sec-0001}
===============

Papillary thyroid carcinoma (PTC) is most common among all thyroid cancers. The most common driver alterations in PTC are point mutations in *BRAF* and *RAS* genes (*KRAS*, *HRAS*, and *NRAS*) and rearrangements of the *RET* gene (*RET/PTC* rearrangements). According to The Cancer Genome Atlas (TCGA) study, these alterations occur in 59.7%, 13%, and 6.3% of the PTC cases, respectively, and the total prevalence of gene rearrangements is 15%.[1](#gcc22737-bib-0001){ref-type="ref"}

Multiple gene rearrangements occur in PTC, and *RET/PTC* are the most prevalent ones.[1](#gcc22737-bib-0001){ref-type="ref"} *RET/PTC* rearrangements are associated with younger age and radiation exposure.[2](#gcc22737-bib-0002){ref-type="ref"} As documented in the previous studies, detection of these alterations in cytological specimens may be helpful in improving the accuracy of the diagnosis of PTC.[3](#gcc22737-bib-0003){ref-type="ref"} Multiple gene rearrangements can be screened using the molecular test ThyroSeq; these rearrangements entail a high risk of cancer.[4](#gcc22737-bib-0004){ref-type="ref"} However, it is worth noting that gene rearrangements can also be found in some benign thyroid diseases.[5](#gcc22737-bib-0005){ref-type="ref"}

In recent years, our knowledge about genomic rearrangements and transcript fusions in PTC has widely expanded, mostly thanks to RNA‐Seq, what led to the detection of numerous novel gene rearrangements in PTC.[1](#gcc22737-bib-0001){ref-type="ref"}, [6](#gcc22737-bib-0006){ref-type="ref"}, [7](#gcc22737-bib-0007){ref-type="ref"}, [8](#gcc22737-bib-0008){ref-type="ref"}, [9](#gcc22737-bib-0009){ref-type="ref"}, [10](#gcc22737-bib-0010){ref-type="ref"}, [11](#gcc22737-bib-0011){ref-type="ref"} The most important was the detection of *ETV6‐NTRK3*, which occurs in 2%‐14.5% of PTC patients.[8](#gcc22737-bib-0008){ref-type="ref"} In PTCs, the most common 5′ partner in gene rearrangements are *RET*, *BRAF*, *NTRK3*, *THADA*, *PPARG*, *NTRK1*, and *ALK*.^1^ All of them, except *THADA*, code for proteins with tyrosine kinase domains.

Our study aimed to detect novel transcript fusions in PTC to expand the knowledge about genetic alterations in this malignancy.

2. MATERIALS AND METHODS {#gcc22737-sec-0002}
========================

2.1. Samples {#gcc22737-sec-0003}
------------

Fresh‐frozen material from 14 PTCs was used in this study. Surgical procedures were performed in Maria Sklodowska‐Curie Institute---Oncology Center, Gliwice Branch. The study was approved by the Bioethics Committee of Maria Sklodowska‐Curie Institute---Oncology Center, Gliwice Branch. Informed consent was obtained from all patients.

The samples were selected from a group, in which common PTC mutations have been already analyzed: point mutations---*BRAF* ^V600E^ and mutations in codons 12, 13, and 61 of *HRAS*, *NRAS*, and *KRAS* genes with Sanger sequencing and rearrangements---*PAX8‐PPARG*, *RET/PTC1*, and *RET/PTC3* with quantitative real‐time polymerase chain reaction (qRT‐PCR). Among 14 samples selected for RNA‐Seq experiment, there was 1 sample positive for *RET/PTC1* rearrangement and 1 sample positive for *RET/PTC3* rearrangement. The remaining 12 samples were negative for *BRAF* ^V600E^ mutation, *HRAS*, *NRAS*, *KRAS* hotspot mutations, *PAX8‐PPARG*, *RET/PTC1* and *RET/PTC3* rearrangements, with the exception of a few cases in which not all mutations were evaluated due to sample availability limitations (details in Supporting Information Table [S1](#gcc22737-supitem-0003){ref-type="supplementary-material"}).

There were 3 males and 11 females in our study group diagnosed with classical (10 cases) and follicular (4 cases) PTC variants. Young patients were preferred during sample selection: the mean age at diagnosis was 24 years, with a median of 26 years (range: 13--40 years). The mean and median tumor diameters were 17 mm and 15 mm, respectively (range 10--34 mm). Four PTCs were multifocal, 5 with capsule invasion, and 1 with vascular invasion. Lateral neck lymph node metastases were present in 7 patients. Neither local recurrence nor distant metastases were present in any patient from the study group. The histopathological characteristics of the tumors are given in Table [1](#gcc22737-tbl-0001){ref-type="table"}.

###### 

Histopathological characteristics of 14 PTC samples included in this study

  Sample   Sex   Age (years)   Histology    Tumor diameter (mm)   Multifocality   Capsule invasion   Metastasis to lateral neck lymph nodes   Vascular invasion
  -------- ----- ------------- ------------ --------------------- --------------- ------------------ ---------------------------------------- -------------------
  NIS164   F     29            Classic      34                    Multifocal      Yes                No                                       No
  NIS203   M     13            Classic      32                    Multifocal      Yes                Yes                                      Yes
  NIS207   F     16            Classic      15                    Multifocal      Yes                No                                       No
  NIS280   F     19            Follicular   10                    Unifocal        No                 No                                       No
  PTC006   M     32            Classic      14                    Unifocal        No                 No                                       No
  PTC100   F     25            Follicular   15                    Multifocal      Yes                Yes                                      No
  PTC102   F     15            Classic      20                    Unifocal        No                 Yes                                      No
  PTC106   F     17            Classic      11                    Unifocal        No                 No                                       No
  PTC113   F     23            Classic      18                    Unifocal        No                 Yes                                      No
  PTC131   F     29            Classic      15                    Unifocal        No                 Yes                                      No
  PTC135   F     29            Follicular   14                    Unifocal        No                 Yes                                      No
  PTC174   M     27            Classic      15                    Unifocal        No                 No                                       No
  PTC18    F     40            Follicular   10                    Unifocal        No                 No                                       No
  PTC181   F     29            Classic      16                    Unifocal        Yes                Yes                                      No

2.2. RNA‐Seq {#gcc22737-sec-0004}
------------

To detect novel fusion transcripts in PTC, we performed paired‐end RNA‐Seq on 12 PTC samples that were negative regarding most common PTC genetic alterations (*BRAF* ^V600E^ mutation, mutations in codons 12, 13, and 61 of *HRAS*, *NRAS*, and *KRAS* genes, *PAX8‐PPARG*, *RET/PTC1*, and *RET/PTC3*). We also performed paired‐end RNA‐Seq experiment on 1 case with *RET/PTC1* and 1 case with *RET/PTC3* as positive controls.

Total RNA was extracted from homogenized frozen tissue using Mini Kits (Qiagen GmbH, Hilden, Germany). RNA quantity was measured by NanoDrop ND‐1000 (Thermo Scientific, Wilmington, DE) minispectrophotometer whereas its quality was estimated by Agilent 2100 using RNA 6000 Nano Assay (Agilent Technologies, Santa Clara, CA). Only high‐quality RNA (RNA Integrity Number \> 6.5) was used. Sequencing libraries were prepared with the TruSeq RNA Sample Preparation Kit v2 SetA (Illumina Inc., San Diego, CA), following the manufacturer\'s protocol.

Oligo(dT) magnetic beads Agencourt Ampure XP (Beckman Coulter Inc. Brea, CA) were used to isolate poly(A) RNA from the total RNA samples. The mRNA was fragmented by heating at 94°C for 8 minutes. First‐strand cDNA was synthesized using random hexamer primers for 10 minutes at 25°C, 50 minutes at 42°C, and 15 minutes at 70°C. After the synthesis of the first strand, dNTPs, DNA Polymerase I and RNaseH were added to synthesize second‐strand cDNA for 1 hour at 16°C. The ends of double‐stranded cDNA were repaired by using End Repair Mix. A single "A" nucleotide was added to the 3′ ends of the cDNA molecules and the fragments were ligated to the paired‐end adapters. The purified cDNA was amplified by 15 cycles of PCR for 10 seconds at 98°C, 30 seconds at 60°C, and 30 seconds at 72°C using PCR primers. The quality of the resulting sequencing libraries were determined on a High Sensitivity DNA Kit using an Agilent 2100 Bioanalyser (Agilent Technologies, Santa Clara, CA) and concentration of the libraries was determined on Qubit (Invitrogen, Carlsbad, CA). The mRNASeq libraries were sequenced on a HiSeq1500 device (Illumina Inc., San Diego, CA) to generate 2×120 or 2×106 bp paired‐end reads.

2.3. RNA‐Seq data analysis {#gcc22737-sec-0005}
--------------------------

Read\'s quality was assessed using FastQC version 0.9.3.[12](#gcc22737-bib-0012){ref-type="ref"} Raw FASTQ data were trimmed and filtered using Prinseq‐lite version 0.20.4, and only high‐quality reads were used in the further analysis.[13](#gcc22737-bib-0013){ref-type="ref"}

Fusion transcripts detection was performed using three bioinformatics tools in order to achieve a high sensitivity: TopHat‐Fusion (TopHat version 2.0.10),[14](#gcc22737-bib-0014){ref-type="ref"} ChimeraScan version 0.4.5,[15](#gcc22737-bib-0015){ref-type="ref"} and SnowShoes‐FTD version 2.0 Build 37.[16](#gcc22737-bib-0016){ref-type="ref"} Fusion transcripts detected with these tools were further filtered with in‐house tools in order to filter out false positive findings (details provided in supplementary methods). Genome version GRCh37/hg19 was used in all these analyses.

The list of fusion transcripts present in normal samples was obtained from the paper published by Babiceanu et al.[17](#gcc22737-bib-0017){ref-type="ref"}

2.4. Validation of detected transcript fusions with Sanger sequencing {#gcc22737-sec-0006}
---------------------------------------------------------------------

Validation of novel transcript fusions was performed with the use of Sanger\'s direct sequencing method on the 3130xl Genetic Analyzer (Life Technologies, Carlsbad, CA) with ABI PRISM 1.1 BigDye Terminator Cycle Sequencing Ready Reaction Kit (Life Technologies). Before sequencing, RNA (200 ng) was converted to cDNA with the Omniscript RT Kit (Qiagen GmbH). The reaction was carried out for 1 hour at 37°C in a volume of 20 μL using a mixture of 1× concentrated buffer (2 μL; Omniscript RT Kit), 5× concentrated dNTPs (2 μL; Omniscript RT Kit), 4 U/μl RT‐O polymerase (1 μL; Omniscript RT Kit), 50 μM random nonamers (1.6 μL), and 1× concentrated RiboLock RNAse inhibitor (1 μL; Fermentas Thermo Fisher Scientific, Waltham, MA). Obtained cDNA was used as a template in PCR reactions, in which each amplicon was amplified using specific primers designed with the Primer3 Input software available on the website <http://frodo.wi.mit.edu>/ (for primer sequences and annealing temperatures used in PCR reactions, see Supporting Information Table [S2](#gcc22737-supitem-0003){ref-type="supplementary-material"}). Each amplicon contained sequences of both rearranged genes. The PCR products were visualized by electrophoresis in a 2% agarose gel in the presence of bromide ethidium (0,3 μL/mL), cleaned with Exo I (volume 0.6 μL; concentration 10 U/μl; Life Technologies) and Sap (volume 0.6 μL; concentration 2 U/μl; Boehring Manheim GmbH, Germany; Life Technologies) enzymes mixture according to manufacturer\'s recommendations and then sequenced as described earlier.

3. RESULTS {#gcc22737-sec-0007}
==========

3.1. Detection of fusion transcripts by RNA‐Seq {#gcc22737-sec-0008}
-----------------------------------------------

In order to detect novel fusion transcripts in PTC, we performed paired‐end RNA‐Seq experiment on 14 PTC tumor samples. After filtering and trimming of raw reads, we obtained an average of 13.5 million read pairs in each sample. The read length was 120 bp in 6 samples and 50 bp in 8 samples (Supporting Information Table [S3](#gcc22737-supitem-0003){ref-type="supplementary-material"}).

We detected 28 fusion events by TopHat‐Fusion, 96 by ChimeraScan, and 34 by SnowShoes‐FTD (Supporting Information Tables [S4‐S6](#gcc22737-supitem-0003){ref-type="supplementary-material"}). In total, we detected 126 fusion events. Seventy‐three of them were read‐throughs or were detected in normal samples as depicted by Babiceanu et al[17](#gcc22737-bib-0017){ref-type="ref"} and these were beyond our interest (Supporting Information Table [S7](#gcc22737-supitem-0003){ref-type="supplementary-material"}). The remaining 53 fusion transcripts, which were not read‐throughs and not detected in normal samples, were further manually inspected (Supporting Information Table [S8](#gcc22737-supitem-0003){ref-type="supplementary-material"}).

We manually selected candidate fusion transcripts potentially tumorigenic, which involved genes with known cancer‐associated functions. We also selected all candidate fusion transcripts that were detected by more than one program. Final list consisted of 18 transcript fusions (Table [2](#gcc22737-tbl-0002){ref-type="table"}), found in 11 of 14 tumor samples.

###### 

List of candidate fusion transcripts detected in PTC with RNA‐Seq method

       Sample   5′ Chromosome   3′ Chromosome   5′ Breakpoint   3′ Breakpoint   5′ Symbol   3′ Symbol   5′ Entrez   3′ Entrez   Exon boundary Fusion[a](#gcc22737-note-0002){ref-type="fn"}   Sanger validation results   Comment
  ---- -------- --------------- --------------- --------------- --------------- ----------- ----------- ----------- ----------- ------------------------------------------------------------- --------------------------- -----------------------------------------------
  1    NIS164   chr8            chr8            134 145 904     38 277 253      *TG*        *FGFR1*     7038        2260        Yes                                                           Positive                    Novel potentially oncogenic fusion transcript
  2    NIS164   chr8            chr8            38 279 315      134 146 920     *FGFR1*     *TG*        2260        7038        Yes                                                           Positive                    Reciprocal of novel fusion transcript
  3    NIS203   chr10           chr10           51 582 939      43 612 032      *NCOA4*     *RET*       8031        5979        Yes                                                           ‐                           Positive control (*RET/PTC3*)
  4    NIS207   chr3            chr1            100 455 548     156 844 363     *TFG*       *NTRK1*     10 342      4914        Yes                                                           ‐                           Known oncogenic fusion transcript
  5    NIS207   chr3            chr1            100 455 560     156 844 363     *TFG*       *NTRK1*     10 342      4914        Yes                                                           ‐                           Known oncogenic fusion transcript
  6    PTC100   chr12           chr15           12 006 495      88 576 276      *ETV6*      *NTRK3*     2120        4916        Yes                                                           ‐                           Known oncogenic fusion transcript
  7    PTC102   chr10           chr10           61 665 880      43 612 032      *CCDC6*     *RET*       8030        5979        Yes                                                           ‐                           Positive control (*RET/PTC1*)
  8    PTC106   chr10           chr10           61 554 231      43 612 032      *CCDC6*     *RET*       8030        5979        Yes                                                           Positive                    Novel isoform of oncogenic fusion transcript
  9    PTC113   chr7            chr7            140 158 807     140 481 493     *MKRN1*     *BRAF*      23 608      673         Yes                                                           ‐                           Known oncogenic fusion transcript
  10   PTC131   chr1            chr1            114 952 806     156 845 312     *TRIM33*    *NTRK1*     51 592      4914        Yes                                                           Positive                    Novel potentially oncogenic fusion transcript
  11   PTC131   chr1            chr1            114 952 806     156 846 192     *TRIM33*    *NTRK1*     51 592      4914        Yes                                                           Negative                    ‐
  12   PTC131   chr1            chr1            45 671 428      223 972 016     *ZSWIM5*    *TP53BP2*   57 643      7159        Yes                                                           Positive                    Novel fusion transcript
  13   PTC131   chr18           chr4            23 847 587      10 080 625      *TAF4B*     *WDR1*      6875        9948        Yes                                                           Positive                    Novel fusion transcript
  14   PTC131   chr2            chr2            204 245 107     42 867 313      *ABI2*      *MTA3*      10 152      57 504      Yes                                                           Positive                    Novel fusion transcript
  15   PTC131   chr6            chr11           157 150 555     14 540 587      *ARID1B*    *PSMA1*     57 492      5682        Yes                                                           Positive                    Novel fusion transcript
  16   PTC135   chr12           chr15           12 006 495      88 576 276      *ETV6*      *NTRK3*     2120        4916        Yes                                                           ‐                           Known oncogenic fusion transcript
  17   PTC174   chr2            chr2            42 522 656      29 446 394      *EML4*      *ALK*       27 436      238         Yes                                                           ‐                           Known oncogenic fusion transcript
  18   PTC181   chr12           chr15           12 006 495      88 576 276      *ETV6*      *NTRK3*     2120        4916        Yes                                                           ‐                           Known oncogenic fusion transcript

Exon boundary fusion is a fusion transcript in which both sides of the junction are known exon boundaries of the parental genes.

The following novel transcript fusions were detected with RNA‐Seq method: *TG‐FGFR1*, *FGFR1‐TG*, two isoforms of *TRIM33‐NTRK1*, *ARID1B‐PSMA1*, *TAF4B‐WDR1*, *ABI2‐MTA3*, *ZSWIM5‐TP53BP2*, and the novel isoform of *CCDC6‐RET. RET/PTC1* and *RET/PTC3* fusion transcripts were found, as expected, in positive control samples. We also detected known oncogenic fusion transcripts: *TFG‐NTRK1*, *ETV6‐NTRK3* (in three samples), *MKRN1‐BRAF*, and *EML4‐ALK*.

3.2. Validation of fusion transcripts {#gcc22737-sec-0009}
-------------------------------------

We performed validation by direct Sanger sequencing for all 9 novel fusion transcripts. We confirmed the existence of 8/9 fusions: *TG‐FGFR1*, *FGFR1‐TG*, one isoform of *TRIM33‐NTRK1* (with a breakpoint in chr1:114952806‐chr1:156845312), *ARID1B‐PSMA1*, *TAF4B‐WDR1*, *ABI2‐MTA3*, *ZSWIM5‐TP53BP2* as well as the novel isoform of *CCDC6‐RET* (Figures [1](#gcc22737-fig-0001){ref-type="fig"} and [2](#gcc22737-fig-0002){ref-type="fig"}; Supporting Information Figures [S1‐S6](#gcc22737-supitem-0002){ref-type="supplementary-material"}). We did not confirm the second *TRIM33‐NTRK1* fusion isoform, with a breakpoint in chr1:114952806‐chr1:156846192. When we used primers designed for that *TRIM33‐NTRK1* isoform, we did not observe the expected sequence.

![The novel *TG‐FGFR1* fusion transcript detected in PTC. The upper image shows the schematic diagram of the predicted fusion protein. The lower image shows the confirmation of the fusion transcript by direct Sanger sequencing. Abbreviations: COesterase, Carboxylesterase family; Ephrin_rec_like, Putative ephrin‐receptor like; ig, Immunoglobulin domain; I‐set, Immunoglobulin I‐set domain; Pkinase_Tyr, Protein tyrosine kinase; SP, signal peptide; Thyroglobulin_1, Thyroglobulin type‐1 repeat; TM, transmembrane region \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](GCC-58-558-g001){#gcc22737-fig-0001}

![The novel *TRIM33‐NTRK1* fusion transcript detected in PTC. The upper image shows the schematic diagram of the predicted fusion protein. The lower image shows the confirmation of the fusion transcript by direct Sanger sequencing. Abbreviations: Bromodomain, Bromodomain; CC, coiled‐coil region; LRR_8, Leucine rich repeat; PHD, PHD‐finger; Pkinase_Tyr, Protein tyrosine kinase; SP, signal peptide; TPKR_C2, Tyrosine‐protein kinase receptor C2 Ig‐like domain; TrkA_TMD, Tyrosine kinase receptor A trans‐membrane domain; zf‐B_box, B‐box zinc finger; zf‐RING_UBOX, RING‐type zinc‐finger \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](GCC-58-558-g002){#gcc22737-fig-0002}

3.3. Novel fusion transcripts {#gcc22737-sec-0010}
-----------------------------

We detected 2 novel in‐frame fusion transcripts, which are potential driver alterations: *TG‐FGFR1* and *TRIM33‐NTRK1*.

We identified a novel fusion of thyroglobulin (*TG*) and fibroblast growth factor receptor 1 (*FGFR1*) in sample NIS164 (Figure [1](#gcc22737-fig-0001){ref-type="fig"}). The sample was a multifocal classic PTC tumor, 34 mm in diameter, with capsule invasion, no metastasis to lateral neck lymph nodes, and no vascular invasion. The patient was a 29‐year‐old female. *TG* and *FGFR1* genes are localized at 8q24 and 8p11. *TG‐FGFR1* juxtaposes exons 1‐47 of *TG* (ENST00000220616) to exons 9‐18 of *FGFR1* (ENST00000447712). The fusion protein is predicted to include 1‐2730 amino acids (AA) of TG and 361‐822 AA of FGFR1. All domains encoded by *TG* and the whole protein kinase domain encoded by *FGFR1* are retained in this fusion. In NIS164 sample harboring *TG‐FGFR1*, also a reciprocal fusion *FGFR1‐TG* was detected, which fuses exons 1‐8 of *FGFR1* to exon 48 of *TG* (Supporting Information Figure [S1](#gcc22737-supitem-0002){ref-type="supplementary-material"}).

We identified a novel fusion of tripartite motif containing 33 (*TRIM33*) and neurotrophic receptor tyrosine kinase 1 (*NTRK1*) in PTC131 sample (Figure [2](#gcc22737-fig-0002){ref-type="fig"}). The sample was a unifocal classic PTC tumor, 15 mm in diameter, with metastasis to lateral neck lymph nodes, no capsule invasion, and no vascular invasion. The patient was a 29‐year‐old female. The *TRIM33* and *NTRK1* genes are localized at 1p13 and 1q23. *TRIM33‐NTRK1* juxtaposes exons 1‐12 of *TRIM33* (ENST00000358465) to exons 12‐17 of *NTRK1* (ENST00000524377). The fusion protein is predicted to include 1‐732 AA of TRIM33 and 452‐796 AA of NTRK1. The whole tyrosine kinase domain encoded by *NTRK1* is retained in fusion.

In the sample PTC131, apart from the novel *TRIM33‐NTRK1* fusion, we detected 4 other novel fusion transcripts of unknown significance: *ZSWIM5‐TP53BP2, TAF4B‐WDR1, ABI2‐MTA3*, and *ARID1B‐PSMA1* (Supporting Information Figures [S2‐S5](#gcc22737-supitem-0002){ref-type="supplementary-material"}). All 4 fusions apart from *ABI2‐MTA3* are in‐frame. *ABI2‐MTA3* is out‐of‐frame and a premature stop codon occurs in 10th codon after the breakpoint.

We also found a novel in‐frame isoform of the known oncogenic fusion *CCDC6‐RET* in PTC106 sample (Supporting Information Figure [S6](#gcc22737-supitem-0002){ref-type="supplementary-material"}). In the novel isoform, exons 1‐8 of *CCDC6* (ENST00000263102) are fused to exons 12‐20 of *RET* (ENST00000355710), in contrary to the most common *CCDC6‐RET* rearrangement encompassing over 98% of cases, in which exon 1 of *CCDC6* is fused to exons 12‐20 of the *RET* gene (Supporting Information Figure [S6](#gcc22737-supitem-0002){ref-type="supplementary-material"}).[18](#gcc22737-bib-0018){ref-type="ref"} The whole protein kinase domain encoded by *RET* is retained in the novel fusion isoform.

3.4. Known fusion transcripts {#gcc22737-sec-0011}
-----------------------------

Using RNA‐Seq, *NCOA4‐RET* (*RET/PTC1*) and *CCDC6‐RET* (*RET/PTC3*) were found, as expected, in positive control samples. In the remaining samples, we also detected in‐frame fusion transcripts already reported in the literature: two isoforms of *TFG‐NTRK1*, *ETV6‐NTRK3* (in 3 samples), *MKRN1‐BRAF,* and *EML4‐ALK* (Supporting Information Figures [S7‐S11](#gcc22737-supitem-0002){ref-type="supplementary-material"}). In all of them, 3′ partner encodes tyrosine kinase domain, and the whole domain is retained in the predicted fusion protein.

In both the *TFG‐NTRK1* isoforms that we detected, a fusion between exon 6 of *TFG* (ENST00000418917 or ENST00000240851) and exon 10 of *NTRK1* (ENST00000524377) was present. The two isoforms differed in the length of exon 6 of the *TFG* gene, which is 129 bp in *TFG* variant ENST00000418917 and 141 bp in *TFG* variant ENST00000240851 (Supporting Information Figures [S7, S8](#gcc22737-supitem-0002){ref-type="supplementary-material"}). In *ETV6‐NTRK3*, the fusion between exon 4 of *ETV6* (ENST00000396373) and exon 14 of *NTRK3* (ENST00000394480) was present (Supporting Information Figure [S9](#gcc22737-supitem-0002){ref-type="supplementary-material"}). We detected *ETV6‐NTRK3* in 3 samples, and it was the most prevalent alteration in our group. Two of three samples harboring *ETV6‐NTRK3* were follicular variant of PTC. In *MKRN1‐BRAF*, the fusion between exon 4 of *MKRN1* (ENST00000255977) and exon 11 of *BRAF* (ENST00000288602) was present (Supporting Information Figure [S10](#gcc22737-supitem-0002){ref-type="supplementary-material"}). In *EML4‐ALK*, the fusion between exon 13 of *EML4* (ENST00000318522) and exon 20 of *ALK* (ENST00000389048) was present (Supporting Information Figure [S11](#gcc22737-supitem-0002){ref-type="supplementary-material"}).

4. DISCUSSION {#gcc22737-sec-0012}
=============

In this study, RNA‐Seq was used to determine the presence of transcript fusions in PTCs. Fourteen PTC samples were examined, negative for the most common point mutations of the *BRAF* and *RAS* genes, and *PAX8‐PPARG* rearrangements, with only 2 harboring *RET/PTC1* and *RET/PTC3* transcript fusions, treated as the positive controls. Among the analyzed samples novel fusion transcripts were found in two samples: *TG‐FGFR1* and *TRIM33‐NTRK1*, 7 demonstrated known fusion transcripts (*ETV6‐NTRK3* in 3 samples, *TFG‐NTRK1*, *EML4‐ALK*, *MKRN1‐BRAF*, and novel isoform of *CCDC6‐RET*) and in 3 PTCs no fusion transcripts were detected. The tumor with *TRIM33‐NTRK1* also carried 4 other transcript fusions of unknown significance: *ARID1B‐PSMA1*, *TAF4B‐WDR1*, *ABI2‐MTA3*, and *ZSWIM5‐TP53BP2*.

*TG‐FGFR1* is a novel potentially oncogenic fusion transcript. TG is a glycoprotein homodimer produced predominantly by the thyroid gland. Only 1 case of *TG* fusion has been described so far in the literature: *TG‐THADA*.[1](#gcc22737-bib-0001){ref-type="ref"} FGFR1, in turn, is a member of the FGFR family, which activation by mutations, amplification, or translocations plays roles in cancer initiation and development.[19](#gcc22737-bib-0019){ref-type="ref"} A number of *FGFR1, FGFR2*, and *FGFR3* rearrangements was identified in different cancers, including bladder cancer, breast cancer, head and neck cancer, lung squamous cell carcinoma, and thyroid cancer.[20](#gcc22737-bib-0020){ref-type="ref"}, [21](#gcc22737-bib-0021){ref-type="ref"}, [22](#gcc22737-bib-0022){ref-type="ref"} The *TG‐FGFR1* fusion transcript found in our PTC sample encodes a tyrosine kinase domain, which, when activated by TG, transmits the activation signal to the downstream effectors. It suggests that the *TG‐FGFR1* may be responsible for cancer initiation and progression. The expression level of *TG‐FGFR1* is driven by the promoter of *TG*, a gene with high expression in the thyroid, which may result in an aberrant overexpression of *TG‐FGFR1*. One of the mechanisms that switches on the kinase domain in the fusion proteins is the dimerization by one of the domains present in the partner protein.[23](#gcc22737-bib-0023){ref-type="ref"} It has been shown that the cholinesterase‐like domain located in C‐terminal part of TG is responsible for dimerization.[24](#gcc22737-bib-0024){ref-type="ref"} This domain is preserved in the TG‐FGFR1 fusion protein and it may cause the FGFR1 domains to dimerize, resulting in activation of FGFR1 tyrosine kinase in the absence of ligands. The same sample harbored in addition a reciprocal fusion *FGFR1‐TG*.

A second novel fusion detected in our PTC samples was the *TRIM33‐NTRK1* rearrangement. *TRIM33* encodes a tripartite motif containing 33, a transcriptional corepressor, also known as *RFG7*. This gene has been demonstrated to create a fusion with the *RET* gene (*TRIM33‐RET*) in radiation‐induced thyroid carcinomas.[25](#gcc22737-bib-0025){ref-type="ref"} Similarly, *NTRK1* is also a known fusion partner gene in PTCs. *NTRK1* rearrangements occur in up to 13% of PTCs (12% in the Polish population).[1](#gcc22737-bib-0001){ref-type="ref"}, [26](#gcc22737-bib-0026){ref-type="ref"}, [27](#gcc22737-bib-0027){ref-type="ref"}, [28](#gcc22737-bib-0028){ref-type="ref"}, [29](#gcc22737-bib-0029){ref-type="ref"} The *TRIM33‐NTRK1* fusion leads to activation of NTRK1 tyrosine kinase domain, which in turn activates downstream effectors. The mechanism of tyrosine kinase activation in TRIM33‐NTRK1 may be similar to that in the TRIM33‐RET fusion protein. *TRIM33* encodes a coiled‐coil domain that allows ligand‐independent dimerization of the chimeric protein and activation of the truncated RET receptor in TRIM33‐RET.[30](#gcc22737-bib-0030){ref-type="ref"} The TRIM33‐NTRK1 fusion, similarly to *TG‐FGFR1* rearrangement, may be a potential oncogene in PTC development. However, only in vitro functional studies can assess the role of the novel fusion proteins TG‐FGFR1 and TRIM33‐NTRK1 in PTC pathogenesis.

An additional 4 rearrangements (*ZSWIM5‐TP53BP2*, *TAF4B‐WDR1*, *ABI2‐MTA3*, and *ARID1B‐PSMA1*) were found in the PTC sample harboring the *TRIM33‐NTRK1* rearrangement. These additional aberrations have not been described in any other cancer, and only *ABI2* and *ARID1B* have been involved in fusion genes. It is hence difficult to define the role of these fusions in tumorigenesis. It is possible that these fusions are a consequence of genomic instability and are secondary phenomena.

*ABI2* is a *KMT2A* translocation partner in acute myeloid leukemia.[31](#gcc22737-bib-0031){ref-type="ref"} ABI2, being a functional homologue of ABI1, is known as an ABL1 regulator and is considered a tumor suppressor due to its inhibitory function in ABL1 signaling. The *MTA3* gene is a member of the metastasis‐associated protein family, identified as key regulators of the epithelial‐mesenchymal transition process and E‐cadherin expression.[32](#gcc22737-bib-0032){ref-type="ref"} *MTA3* has been described to be under‐expressed in some malignancies, including breast cancer, ovarian cancer, gastroesophageal junction adenocarcinoma or endometrial cancer, and even as a suppressor of metastases in these tumors.[33](#gcc22737-bib-0033){ref-type="ref"}, [34](#gcc22737-bib-0034){ref-type="ref"}, [35](#gcc22737-bib-0035){ref-type="ref"} Shan et al[36](#gcc22737-bib-0036){ref-type="ref"} described decreased *MTA3* expression in glioma and its association with prognosis, which suggests that *MTA3* is a suppressor gene in this malignancy. Interestingly, the *ABI2‐MTA3* fusion, found in our set of PTC samples, is out‐of‐frame and a premature stop codon occurs in 10th codon after the breakpoint, which may lead to silencing of *MTA3* expression. As regards the remaining 3 additional alterations, *ZSWIM5‐TP53BP2*, *TAF4B‐WDR1*, and *ARID1B‐PSMA1*, they all represent in‐frame fusions.

Fusion gene partners of the *TAF4B‐WDR1* are the TATA‐box binding protein associated factor 4b (*TAF4B*), involved in initiation of transcription of genes by RNA polymerase II, and WD repeat domain 1 (WDR1) involved in protein--protein interactions due to WD domains. *WDR1* plays a crucial role in cytokinesis and cell migration and may be important in the ability of cancer cells to proliferate and invade surrounding tissues.[37](#gcc22737-bib-0037){ref-type="ref"}, [38](#gcc22737-bib-0038){ref-type="ref"} Overexpression of *WDR1* was reported in different cancers, including breast cancer, ovarian carcinoma, and thyroid neoplasia.[39](#gcc22737-bib-0039){ref-type="ref"}, [40](#gcc22737-bib-0040){ref-type="ref"}, [41](#gcc22737-bib-0041){ref-type="ref"}

The fusion transcript *ZSWIM5‐TP53BP2* is made of zinc finger SWIM‐type containing 5 gene (*ZSWIM5*) and tumor protein TP53 binding protein 2 (*TP53BP2*, also known as *ASPP2*). TP53BP2 is a member of the ASPP (apoptosis‐stimulating protein of p53) family of TP53 interacting proteins, involved in apoptosis and cell growth regulation. It has been demonstrated that TP53BP2 plays a role as a tumor suppressor[42](#gcc22737-bib-0042){ref-type="ref"} via interactions between Ank/SH3 domains, present in TP53BP2, and numerous partner proteins like TP53, NFKB1, and BCL2.[43](#gcc22737-bib-0043){ref-type="ref"} The fusion transcript, detected by us, retained the SH3 domain; however, it does not have ankyrin (Ank) repeats. Lack of these domains may inhibit *TP53BP2* tumor suppressor functions.

The last fusion, accompanying the *TRIM33‐NTRK1* rearrangement, is the *ARID1B‐PSMA1* fusion. *ARID1B* (AT‐rich interaction domain 1B) encodes a protein that is a component of the SWI/SNF chromatin remodeling complex, which may play a role in cell‐cycle activation. Tumor suppressor activity of ARID1B has been demonstrated in vitro in pancreatic cancer cells.[44](#gcc22737-bib-0044){ref-type="ref"} Moreover, deletions and mutations of this gene have been reported in hepatocellular carcinoma, childhood neuroblastoma, PTC, and other types of cancer.[45](#gcc22737-bib-0045){ref-type="ref"} *ARID1B* has also been identified as an additional *ZNF384* fusion partner in pediatric acute lymphoblastic leukemia.[46](#gcc22737-bib-0046){ref-type="ref"} *PSMA1* (proteasome subunit alpha 1), in turn, was shown to be up‐regulated in a number of cancers.[47](#gcc22737-bib-0047){ref-type="ref"}

We also detected novel in‐frame isoform of the known oncogenic fusion *CCDC6‐RET*, which similarly to other *RET* rearrangements, also retained the *RET* tyrosine kinase domain leading to *RET* activation.

In our group of samples, we also found 4 oncogenic fusions already reported in the literature: *TFG‐NTRK1, ETV6‐NTRK3, MKRN1‐BRAF*, and *EML4‐ALK. TFG‐NTRK1* was previously reported in only a few PTC cases.[27](#gcc22737-bib-0027){ref-type="ref"}, [48](#gcc22737-bib-0048){ref-type="ref"}, [49](#gcc22737-bib-0049){ref-type="ref"} However, it was not reported in other cancers.[18](#gcc22737-bib-0018){ref-type="ref"}, [50](#gcc22737-bib-0050){ref-type="ref"} The longer of two isoforms detected in our study, TFG (exon 6 of ENST00000240851)---NTRK1 (exon 10 of ENST00000524377), has been already reported in PTC.[1](#gcc22737-bib-0001){ref-type="ref"}, [51](#gcc22737-bib-0051){ref-type="ref"} *ETV6‐NTRK3* was the most prevalent alteration in PTC set analyzed by us, as it was found in 3 samples. According to the literature, the *ETV6‐NTRK3* occurs in 2%‐14.5% of PTC patients.[8](#gcc22737-bib-0008){ref-type="ref"} It also occurs in cancers of the salivary gland, kidney, and other tissues.[18](#gcc22737-bib-0018){ref-type="ref"}, [50](#gcc22737-bib-0050){ref-type="ref"} Two of the three samples harboring *ETV6‐NTRK3* were follicular variants of PTCs. This is in agreement with recent findings that most post‐Chernobyl PTCs in which *ETV6‐NTRK3* was identified were classified as follicular variant of PTC.[6](#gcc22737-bib-0006){ref-type="ref"}, [8](#gcc22737-bib-0008){ref-type="ref"} The isoform detected in our study, which juxtaposes exon 4 of *ETV6* (ENST00000396373) and exon 14 of *NTRK3* (ENST00000394480), has been reported in PTC[1](#gcc22737-bib-0001){ref-type="ref"}, [6](#gcc22737-bib-0006){ref-type="ref"}, [8](#gcc22737-bib-0008){ref-type="ref"}, [51](#gcc22737-bib-0051){ref-type="ref"} and gastrointestinal stromal tumor.[52](#gcc22737-bib-0052){ref-type="ref"} *MKRN1‐BRAF* has been reported in a few cases of PTC.[1](#gcc22737-bib-0001){ref-type="ref"}, [7](#gcc22737-bib-0007){ref-type="ref"} It was also described to be present in anaplastic thyroid cancer, pilocytic astrocytoma, head and neck neuroendocrine carcinoma, colon adenocarcinoma, and low‐grade serous ovarian cancer.[53](#gcc22737-bib-0053){ref-type="ref"}, [54](#gcc22737-bib-0054){ref-type="ref"}, [55](#gcc22737-bib-0055){ref-type="ref"}, [56](#gcc22737-bib-0056){ref-type="ref"} The isoform detected in our study, which juxtaposes exon 4 of *MKRN1* (ENST00000255977) to exon 11 of *BRAF* (ENST00000288602), has been reported in pilocytic astrocytoma,[54](#gcc22737-bib-0054){ref-type="ref"} colon adenocarcinoma[55](#gcc22737-bib-0055){ref-type="ref"} and in low‐grade serous ovarian cancer.[56](#gcc22737-bib-0056){ref-type="ref"} *EML4‐ALK* was reported in PTC in a number of studies.[1](#gcc22737-bib-0001){ref-type="ref"}, [9](#gcc22737-bib-0009){ref-type="ref"}, [57](#gcc22737-bib-0057){ref-type="ref"}, [58](#gcc22737-bib-0058){ref-type="ref"} It also occurs in about 7% cases of non‐small‐cell lung cancer and in other cancers.[50](#gcc22737-bib-0050){ref-type="ref"}, [59](#gcc22737-bib-0059){ref-type="ref"} The isoform detected in our study, which juxtaposes exon 13 of *EML4* (ENST00000318522) and exon 20 of *ALK* (ENST00000389048) was reported in lung carcinoma[59](#gcc22737-bib-0059){ref-type="ref"} and papillary thyroid carcinoma.[9](#gcc22737-bib-0009){ref-type="ref"}, [57](#gcc22737-bib-0057){ref-type="ref"}

Although the number of analyzed PTC cases is small, they were carefully selected, and only young PTC patients without known somatic mutations of the *BRAF* and *RAS* genes, *PAX8‐PPARG*, *RET/PTC1*, and *RET/PTC3* rearrangements were taken into consideration. We found new fusion transcripts with a potential oncogenic role and a number of known rearrangements. Our study shows that although large analyses like TCGA study gave us a lot of new data about PTC biology, still some information is missing, and further analyses are needed. There is no doubt that better understanding of molecular PTC background will open new diagnostic and therapeutic possibilities.
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**Supporting Information Figure S1** Novel *FGFR1‐TG* fusion transcript detected in PTC. The upper image shows the schematic diagram of the predicted fusion protein. The lower image shows the confirmation of the fusion transcript by direct Sanger sequencing. Abbreviations: COesterase, Carboxylesterase family; Ephrin_rec_like, Putative ephrin‐receptor like; I‐set, Immunoglobulin I‐set domain; ig, Immunoglobulin domain; Pkinase_Tyr, Protein tyrosine kinase; SP, signal peptide; Thyroglobulin_1, Thyroglobulin type‐1 repeat; TM, transmembrane region

**Supporting Information Figure S2**. Novel *ZSWIM5‐TP53BP2* fusion transcript detected in PTC. The upper image shows the schematic diagram of the predicted fusion protein. The lower image shows the confirmation of the fusion transcript by direct Sanger sequencing. Abbreviations: Ank_2, Ankyrin repeats (3 copies); CC, coiled‐coil region; SH3_1, SH3 domain

**Supporting Information Figure S3**. Novel *TAF4B‐WDR1* fusion transcript detected in PTC. The upper image shows the schematic diagram of the predicted fusion protein. The lower image shows the confirmation of the fusion transcript by direct Sanger sequencing. Abbreviations: CC, coiled‐coil region; TAF4, Transcription initiation factor TFIID component TAF4 family; TAFH, NHR1 homology to TAF; WD40, WD domain, G‐beta repeat

**Supporting Information Figure S4**. Novel *ABI2‐MTA3* fusion transcript detected in PTC. The upper image shows the schematic diagram of the predicted fusion protein. The lower image shows the confirmation of the fusion transcript by direct Sanger sequencing. Abbreviations: Abi_HHR, Abl‐interactor HHR; BAH, BAH domain; ELM2, ELM2 domain; GATA, GATA zinc finger; MTA_R1, MTA R1 domain; Myb_DNA‐binding, Myb‐like DNA‐binding domain; SH3_9, Variant SH3 domain

**Supporting Information Figure S5**. Novel *ARID1B‐PSMA1* fusion transcript detected in PTC. The upper image shows the schematic diagram of the predicted fusion protein. The lower image shows the confirmation of the fusion transcript by direct Sanger sequencing. Abbreviations: ARID, ARID/BRIGHT DNA binding domain; BAF250_C, SWI/SNF‐like complex subunit BAF250/Osa; CC, coiled‐coil region; Proteasome, Proteasome subunit; Proteasome_A\_N, Proteasome subunit A N‐terminal signature

**Supporting Information Figure S6**. Novel isoform of *CCDC6‐RET* fusion transcript detected in PTC. The upper image shows the schematic diagram of the predicted fusion protein. The lower image shows the confirmation of the fusion transcript by direct Sanger sequencing. Abbreviations: Cadherin, Cadherin domain; CC, coiled‐coil region; DUF2046, Uncharacterized conserved protein H4 (DUF2046); Pkinase_Tyr, Protein tyrosine kinase; RET_CLD1, RET Cadherin like domain 1; RET_CLD3, RET Cadherin like domain 3; RET_CLD4, RET Cadherin like domain 4; SP, signal peptide; TM, transmembrane region

**Supporting Information Figure S7**. Known *TFG‐NTRK1* fusion event detected in PTC. Breakpoint: chr3:100455548‐ chr1:156844363. Abbreviations: CC, coiled‐coil region; LRR_8, Leucine rich repeat; PB1, PB1 domain; Pkinase_Tyr, Protein tyrosine kinase; SP, signal peptide; TPKR_C2, Tyrosine‐protein kinase receptor C2 Ig‐like domain; TrkA_TMD, Tyrosine kinase receptor A trans‐membrane domain

**Supporting Information Figure S8**. Known *TFG‐NTRK1* fusion event detected in PTC. Breakpoint: chr3:100455560‐chr1:156844363. Abbreviations: CC, coiled‐coil region; LRR_8, Leucine rich repeat; PB1, PB1 domain; Pkinase_Tyr, Protein tyrosine kinase; SP, signal peptide; TPKR_C2, Tyrosine‐protein kinase receptor C2 Ig‐like domain; TrkA_TMD, Tyrosine kinase receptor A trans‐membrane domain

**Supporting Information Figure S9**. Known *ETV6‐NTRK3* fusion event detected in PTC. Abbreviations: Ets, Ets‐domain; I‐set, Immunoglobulin I‐set domain; ig, Immunoglobulin domain; LRR_8, Leucine rich repeat; LRRNT, Leucine rich repeat N‐terminal domain; Pkinase_Tyr, Protein tyrosine kinase; SAM_PNT, Sterile alpha motif (SAM)/Pointed domain; SP, signal peptide; TM, transmembrane region; TPKR_C2, Tyrosine‐protein kinase receptor C2 Ig‐like domain

**Supporting Information Figure S10**. Known *MKRN1‐BRAF* fusion event detected in PTC. Abbreviations: C1_1, Phorbol esters/diacylglycerol binding domain (C1 domain); CC, coiled‐coil region; MKRN1_C, E3 ubiquitin‐protein ligase makorin‐1, C‐terminal; Pkinase_Tyr, Protein tyrosine kinase; RBD, Raf‐like Ras‐binding domain; zf‐C3HC4, Zinc finger, C3HC4 type (RING finger); zf‐CCCH_4, CCCH‐type zinc finger

**Supporting Information Figure S11**. Known *EML4‐ALK* fusion event detected in PTC. Abbreviations: CC, coiled‐coil region; Gly_rich, Glycine rich protein; HELP, HELP motif; MAM, MAM domain, meprin/A5/mu; Pkinase_Tyr, Protein tyrosine kinase; SP, signal peptide; TM, transmembrane region; WD40, WD domain, G‐beta repeat
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**Supporting Information Table S1**. Mutations in analyzed samples detected by Sanger sequencing and qRT‐PCR. 0---negative, 1---positive, ND---not done.

**Supporting Information Table S2**. Primers sequences and annealing temperatures used in PCR reactions

**Supporting Information Table S3**. Summary of data generated in RNA‐seq experiment (after applying filtering and trimming of reads)

**Supporting Information Table S4**. TopHat Fusion output (after applying in‐house filters)

**Supporting Information Table S5**. ChimeraScan output (after applying in‐house filters)

**Supporting Information Table S6**. SnowShoes output

**Supporting Information Table S7**. Combined outputs from TopHat, ChimeraScan and SnowShoes: read‐through gene fusions and fusions occurring in normal samples (as depicted by Babiceanu et al.)

**Supporting Information Table S8**. Combined outputs from TopHat, ChimeraScan and SnowShoes: gene fusions that are not read‐through and do not occur in normal samples (potential rearrangements)
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